Duke Study Analyzes Impact of Broad Claims in Myriad BRCA1 Patent, Suggests USPTO Errors

Duke University researchers found that 80 percent of cDNA and mRNA in GenBank contain at least one oligonucleotide covered by a claim in one of Myriad's BRCA patents.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.